Chiara Sugarmann

机构：Janssen (United States) · ORCID：0000-0003-2040-6983

发表论文 7 篇 · 总被引 174 次 · h-index 5

代表论文

Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study (2019 · Clinical and Applied Thrombosis/Hemostasis · 被引 66)
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study (2021 · American Heart Journal · 被引 44)
Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients (2021 · Journal of the American Heart Association · 被引 43)
Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study (2019 · Blood · 被引 9)
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials (2022 · Circulation · 被引 8)
Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis (2021 · Clinical and Applied Thrombosis/Hemostasis · 被引 4)